ABERA: Transition to clinical-stage vaccines, strong financing, and expanded R&D drive future growth

About this update from Abera Bioscience Ab

Strong progress in vaccine development with transition to clinical phase, robust financing from grants and share issues, and a widened pipeline. Net loss increased due to higher R&D costs, but cash position and equity improved significantly.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Abera Bioscience Ab